Search research articles
Contact Us
Filters
Showing results (1-10 of 71) with videos related to
Page
of 8
Sort By:
Evidence-Based Medicine
|
February 2, 2012
Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naive patients with genotype 1 hepatitis C virus infection
Mark Danta
Nature Clinical Practice. Gastroenterology & Hepatology
|
November 3, 2005
Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
Geoffrey Dusheiko, Mark Danta
Drugs of Today (Barcelona, Spain : 1998)
|
August 29, 2007
Telbivudine for the treatment of chronic hepatitis B
Geoffrey Dusheiko, Mark Danta
Expert Opinion on Pharmacotherapy
|
December 23, 2021
Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection
Rachael Jacob, Mark Danta
Annals of Translational Medicine
|
May 14, 2023
Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)-will there ever be enough data?
Harry Crane, Mark Danta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 19, 2013
Spread of hepatitis C virus infection in men who have sex with men
Daniel Bradshaw, Mark Danta
Current Opinion in HIV and AIDS
|
October 18, 2011
Transmission of HCV in HIV-positive populations
Mark Danta, Alison J Rodger
Neurology
|
November 24, 2020
Author response: Meta-analysis of magnetic resonance spectroscopy in the diagnosis of hepatic encephalopathy
Mark Danta, Georgia Zeng, Sara Montagnese
Internal Medicine Journal
|
January 16, 2025
Patient-driven personal importation in the face of cost barriers to care: can we do better?
Narcyz Ghinea, Hazel Heal, Mark Danta
European Journal of Gastroenterology & Hepatology
|
April 14, 2005
The surveillance and diagnosis of hepatocellular carcinoma
Mark Danta, Eleanor Barnes, Geoffrey Dusheiko
Page
of 8
Search research articles
Search
Showing results (1-10 of 71) with videos related to
Sort By:
Page
of 8
Evidence-Based Medicine
|
February 2, 2012
Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naive patients with genotype 1 hepatitis C virus infection
Mark Danta
Nature Clinical Practice. Gastroenterology & Hepatology
|
November 3, 2005
Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
Geoffrey Dusheiko, Mark Danta
Drugs of Today (Barcelona, Spain : 1998)
|
August 29, 2007
Telbivudine for the treatment of chronic hepatitis B
Geoffrey Dusheiko, Mark Danta
Expert Opinion on Pharmacotherapy
|
December 23, 2021
Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection
Rachael Jacob, Mark Danta
Annals of Translational Medicine
|
May 14, 2023
Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)-will there ever be enough data?
Harry Crane, Mark Danta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 19, 2013
Spread of hepatitis C virus infection in men who have sex with men
Daniel Bradshaw, Mark Danta
Current Opinion in HIV and AIDS
|
October 18, 2011
Transmission of HCV in HIV-positive populations
Mark Danta, Alison J Rodger
Neurology
|
November 24, 2020
Author response: Meta-analysis of magnetic resonance spectroscopy in the diagnosis of hepatic encephalopathy
Mark Danta, Georgia Zeng, Sara Montagnese
Internal Medicine Journal
|
January 16, 2025
Patient-driven personal importation in the face of cost barriers to care: can we do better?
Narcyz Ghinea, Hazel Heal, Mark Danta
European Journal of Gastroenterology & Hepatology
|
April 14, 2005
The surveillance and diagnosis of hepatocellular carcinoma
Mark Danta, Eleanor Barnes, Geoffrey Dusheiko
Page
of 8